The estimated Net Worth of Michael J Coyle is at least $16.3 Million dollars as of 15 November 2019. Mr. Coyle owns over 36,874 units of Haemonetics stock worth over $16,311,103 and over the last 10 years he sold HAE stock worth over $0. In addition, he makes $0 as Independent Director at Haemonetics.
Michael has made over 4 trades of the Haemonetics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 36,874 units of HAE stock worth $1,431,080 on 15 November 2019.
The largest trade he's ever made was exercising 178,219 units of Haemonetics stock on 22 August 2018 worth over $6,595,885. On average, Michael trades about 9,149 units every 16 days since 2015. As of 15 November 2019 he still owns at least 225,136 units of Haemonetics stock.
You can see the complete history of Mr. Coyle stock trades at the bottom of the page.
Michael J. Coyle serves as Independent Director of the Company. Mr. Coyle has served as Executive Vice President and Group President, Cardiac and Vascular Group of Medtronic plc (and its predecessor, Medtronic, Inc.), a global medical device company, where he oversees four of the company’s business divisions, providing strategic direction and ensuring the alignment of integrated growth plans and cross-functional synergies. Mr. Coyle previously served as President of the Cardiac Rhythm Management division at St. Jude Medical Inc. from 2001 to 2007 and earlier in his career held numerous leadership positions at St. Jude and Eli Lilly & Company. Mr. Coyle has previously served on the boards of two NASDAQ-listed medical device companies responsible for making catheter-based products and holds six U.S. patents related to cardiovascular medical device products and technologies.
Michael Coyle is 58, he's been the Independent Director of Haemonetics since 2020. There are 7 older and 5 younger executives at Haemonetics. The oldest executive at Haemonetics Corp. is Richard Meelia, 71, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy und Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: